Are you aware that CMS published a new report on Healthcare Fraud Prevention in May?
Do you understand its potential implications for your lab? Learn from our experts how to avoid violations, and action steps to take should you become a target of an enforcement procedure!
A report issued in May 2018 from the Healthcare Fraud Prevention Partnership, a public-private partnership of healthcare payers and allied organizations, suggests even more should be done to combat potential fraud and abuse in the clinical laboratory industry. It seems there is always a new wave of “bad players” engaged in new schemes of improper billing and fraudulent activities that result in government and commercial payors continuing to train the spotlight on the majority of the clinical laboratory industry who consistently strive to do everything right.
Due to heightened investigative activity by the U.S. Department of Justice (DOJ) and HHS Office of Inspector General (OIG), as well an increased focus on criminal sanctions and individual accountability, the legal and financial implications to your laboratory or pathology group for non-compliance can be significant. On top of all that, the Bipartisan Budget Act of 2018 has increased the potential fines under the Anti-Kickback Statute from $25,000 to $100,000 per violation and doubled potential prison time from 5 to 10 years, as well as increased civil monetary penalties applicable to violations of the Civil Monetary Penalties Law, which had already been increased previously to adjust for inflation under the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015.
Taken together, these potential repercussions for your laboratory are grave cause for concern, and are the reasons why you need to come up to speed fully and immediately on all of the issues. To keep your lab ahead of these powerful developments, order the webinar “The New CMS White Paper on Healthcare Fraud Prevention: What You Need to Know, How You Can Avoid its Consequences, and What to Do if You Are a Target of This Enforcement,” recorded Wednesday, July 18, 2018. Charles Dunham, a recognized health care attorney in the clinical laboratory industry, and Melissa Jampol, a former Assistant U.S. Attorney in the Healthcare and Government Fraud Unit for the District of New Jersey—both from Epstein Becker & Green, PC—share invaluable insights into recent examples of government investigative actions (civil, criminal and administrative) and commercial payor audits concerning clinical laboratories, and provide you with indispensable advice you can use immediately to design and implement a compliance program that will proactively protect you from possible pitfalls.
Epstein, Becker & Green is a national health law firm that represents healthcare providers and suppliers in numerous industries and practice areas, and brings to this session immense value for you from Dunham and Jampol. Because of their deep knowledge and understanding of government investigations and enforcement actions, the webinar becomes an ideal opportunity for you and your laboratory managers, compliance staff, and management team to take advantage of unparalleled experience and best practice recommendations in responding to investigations and achieving regulatory compliance.
DATE: Recorded July 18, 2018
ORDER CD: Click here
With this webinar, you’ll get the information you need be proactive in your laboratory business, keep your lab safe, and be armed with the necessary steps you should take in the event response to an issue is required. What’s more, for one low price—just $245—you and your entire team at one location can take part in this valuable learning session.
Whether you’re a pathologist, laboratory executive or manager, compliance officer—or any member of the laboratory management team for whom it is critical to understand the recommendations and best practices designed to avoid compliance violations and to mitigate potential problems, this is one webinar you can’t afford to miss.
Your webinar registration includes:
Order the CD today!
Charles C. Dunham, IV
Epstein Becker & Green, P.C.
New York, NY
Charles Dunham’s national practice includes representation of healthcare providers and health-related entities, with a focus on clinical and anatomic pathology laboratories, hospitals and health systems, physician group practices and networks, telehealth practitioners and providers, and health IT companies. Dunham provides general counsel on corporate and health regulatory compliance, as well as transactional matters, including mergers, acquisitions and business ventures. He also represents clients in government enforcement actions and commercial litigation.
Melissa L. Jampol
Epstein Becker & Green, P.C.
New York, NY
Melissa Jampol specializes in the Health Care and Life Sciences and Litigation practices, in the New York and Newark office of Epstein Becker Green. A former federal and state prosecutor, Jampol represents health care organizations including health care systems, clinical labs, physician group practices, pharmacies, and other health care providers, officers and directors, in a variety of enforcement matters at both state and federal levels. She previously served as an Assistant U.S. Attorney in the U.S. Attorney’s Office for the District of New Jersey and as an Assistant District Attorney at the New York County (Manhattan) District Attorney’s Office. Jampol was part of the prosecution team during the lengthy federal investigation into Biodiagnostic Laboratory Services.